Get the Facts

Find what you need to know
in our brochures.

DOWNLOAD

Get our
Press Kit

Official information for
articles and stories.

GET PRESS KIT

Multiple Myeloma News

Sort by Category:

The Multiple Myeloma Research Foundation Commends the U.S. Food and Drug Administration (FDA) Approval of Novartis’ Farydak (Panobinostat) for Multiple Myeloma

The Multiple Myeloma Research Foundation (MMRF) praises the Food and Drug Administration’s (FDA) decision to approve Farydak (panobinostat) for patients with advanced myeloma and treatment resistant multiple myeloma. Specifically, Farydak is approved in combination with Velcade (bortezomib) and dexamethasone for the treatment of multiple myeloma for patients who have received at least two prior standard therapies, including bortezomib and an immunomodulatory (IMiD) agent. Read More

February 24, 2015

Statement from the Multiple Myeloma Research Foundation Regarding the Decision by the U.S. Food and Drug Administration (FDA) to Approve Celgene’s REVLIMID® (Lenalidomide) in Newly Diagnosed Multiple Myeloma Patients

The Multiple Myeloma Research Foundation (MMRF) today issued the following statement regarding the U.S. Food and Drug Administration’s (FDA) approval of Celgene’s REVLIMID® (Lenalidomide) in combination with dexamethasone for the treatment of newly diagnosed multiple myeloma patients who were not eligible for a stem cell transplant. Read More

February 18, 2015

Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma

Vij R, Kumar S, Zhang MJ, Zhong X, Huang J, Dispenzieri A, Abidi MH, Bird JM, Freytes CO, Gale RP, Kindwall-Keller TL, Kyle RA, Landsburg DJ, Lazarus HM, Munker R, Roy V, Sharma M, Vogl DT, Wirk B, Hari PN. Read More

February 17, 2015

Page 1 of 3312345...102030...Last »